Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their application

A type 2 diabetes and kit technology, applied in the field of risk biomarkers and kits, can solve the problems of time-consuming and labor-consuming, expensive MCI diagnostic methods, etc., and achieve fast detection speed, low cost and easy acceptance

Active Publication Date: 2022-05-24
HUAZHONG UNIV OF SCI & TECH
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to provide a biomarker and kit for predicting the risk of MCI in patients with type 2 diabetes and its application in order to overcome the problems of expensive, time-consuming and labor-intensive diagnostic methods for MCI in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their application
  • Biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their application
  • Biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] The inventors of the present invention have found in the previous research process that the total content of GSK-3β in platelets (Total-GSK-3β) in people with type 2 diabetes mellitus associated with MCI (T2DM-MCI) is comparable to that of p-GSK-3β- The ratio of Ser9 content (rGSK3β), the ratio of plasma Aβ42 and Aβ40 levels (Aβ42 / 40) will be significantly higher than that of type 2 diabetes non-MCI (T2DM-nMCI) population. Therefore, the inventors of the present invention performed proteomic screening on the platelets of patients with T2DM-MCI and T2DM-nMCI, and analyzed the correlation with the detection results of Aβ42 / 40, rGSK3β and MMSE in patients with T2DM-MCI and T2DM-nMCI , aimed at discovering potential biomarkers.

[0046] The relevant detection methods are as follows:

[0047] 1. The specific steps of OPTN level detection include: a: Collect blood from patients with type 2 diabetes, and then conduct blood tissue separation to extract platelets;

[0048] d: ...

Embodiment 2

[0057] On the basis of the test results in Example 1, this example further analyzes the protein level of OPTN in the platelets of the T2DM-MCI population and in the brains of AD transgenic mice (5XFAD).

[0058] The diagnosis of MCI in patients with type 2 diabetes was carried out by MMSE analysis method, and the people in the group were divided into T2DM-nMCI and T2DM-MCI. The MMSE score of T2DM-nMCI was 28.67, and the MMSE score of T2DM-MCI was 22.97. The platelet OPTN level of the personnel in the group was detected by immunostaining method, and the results were as follows: figure 2 As shown (mean±SEM; ***p<0.001; T2DM-nMCI: n=30; T2DM-MCI: n=34) It can be seen from the figure that the platelet OPTN in patients with type 2 diabetes and MCI was significantly increased.

[0059] The correlation between the level of OPTN protein in the brain of AD transgenic mice and age was detected, and the results were as follows: image 3 Shown (mean±SEM; *P<0.05, **P<0.01, ***P<0.001, n...

Embodiment 3

[0061] In this example, OPTN was used as a biomarker to establish a diagnostic model, and whether the protein level of OPTN was increased was used to predict MCI in T2DM patients. Test results such as Figure 4 As shown, it can be seen from the figure that AUC=0.799, accuracy=76.6%, threshold=1.23, sensitivity=70.6%, specificity=83.3%.

[0062] Therefore, it can be seen from the above examples that when the OPTN level in platelets of patients with type 2 diabetes rises to 1.23 times (cutoff value) or above the reference level, there is a high risk of MCI. Using OPTN as a biomarker to predict the risk of MCI in patients with type 2 diabetes has the characteristics of high accuracy, high sensitivity and good specificity.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine, and discloses a biomarker and kit for predicting the risk of MCI in patients with type 2 diabetes and applications thereof. The biomarker is OPTN. This biomarker can predict the risk of MCI in patients with type 2 diabetes. It has the characteristics of high accuracy, fast detection speed, low cost, less trauma, and easy acceptance by patients. It provides a scientific and effective diagnostic solution for MCI in patients with type 2 diabetes. . The kit can screen for MCI in a large population, and only needs to collect peripheral blood to complete the detection, making it possible to screen a large-scale elderly population.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a biomarker and kit for predicting the risk of MCI in patients with type 2 diabetes and applications thereof. Background technique [0002] Alzheimer's disease (AD) is a primary degenerative disease of the central nervous system and the most common type of dementia. The main clinical symptom of AD is slow cognitive decline, including progressive loss of memory, logical reasoning ability and language function, and finally develops into severe dementia. [0003] At present, there is still a lack of early diagnostic measures for AD, and irreversible brain damage often occurs when patients see a doctor, resulting in poor treatment effects. Therefore, the discovery of early risk factors is of great significance for early diagnosis and intervention. Cognitive impairment in type 2 diabetes mellitus (T2DM) is an independent risk factor for AD. The incidence of T2DM is high and tends to increase...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2800/042
Inventor 王建枝
Owner HUAZHONG UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com